{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:37:42Z","timestamp":1793659062137,"version":"4.5.1"},"reference-count":10,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2025,1]]},"abstract":"\n Purpose:<\/jats:bold>\n To examine the risks associated with the use of pilocarpine hydrochloride 1.25% ophthalmic solution prescribed for presbyopia.\n Methods:<\/jats:bold>\n The adverse ocular events reported after the use of pilocarpine were compared with the symptoms experienced by a 62-year-old presbyopic man shortly after he took pilocarpine.\n Results:<\/jats:bold>\n Soon after instilling pilocarpine, the patient reported symptoms, including eye pain, hazy vision, and floaters. An examination showed a horseshoe retinal tear, vitreous hemorrhage, and posterior vitreous detachment, for which the patient received extensive clinical and surgical management.\n Conclusions:<\/jats:bold>\n This case highlights the need for comprehensive eye examinations and patient education about the warning signs of retinal tears or detachments before prescribing pilocarpine for presbyopia. Vigilance regarding the potential rare adverse effects of this new pilocarpine ophthalmic solution is warranted.\n <\/jats:p>","DOI":"10.1177\/24741264241255589","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T08:59:00Z","timestamp":1717145940000},"page":"105-108","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Horseshoe Retinal Tear Minutes After Use of a New Pilocarpine Formulation in a Presbyopic, Emmetropic Man"],"prefix":"10.1177","volume":"9","author":[{"given":"Isabel C.","family":"Eaddy","sequence":"first","affiliation":[{"name":"Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obadah","family":"Moushmoush","sequence":"additional","affiliation":[{"name":"MedStar Georgetown University Hospital, Ophthalmology, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3443-329X","authenticated-orcid":false,"given":"Omar","family":"Sabbagh","sequence":"additional","affiliation":[{"name":"West Virginia University, Morgantown, WV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhi Dean","family":"Barazi","sequence":"additional","affiliation":[{"name":"Rice University, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Sabbagh","sequence":"additional","affiliation":[{"name":"George Washington University School of Medicine and Health Sciences, Ophthalmology, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"Allergan. A phase 3 efficacy study of pilocarpine HCl ophthalmic aolution (AGN-190584) in participants with presbyopia (GEMINI 2). (NCT03857542). 2019. Accessed November 2022. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03857542"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(82)34866-6"},{"issue":"1643","key":"e_1_3_2_4_2","first-page":"17","article-title":"Vuity - pilocarpine ophthalmic solution for presbyopia","volume":"64","author":"Abramowicz M","year":"2022","unstructured":"Abramowicz M, Pflomm J, Shah B, et al. Vuity - pilocarpine ophthalmic solution for presbyopia. Med Lett Drugs Ther. 2022; 64(1643):17-18.","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.0059"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.13989"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000001309"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2022.05.011"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20220629-01"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(79)35529-4"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116735"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264241255589","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264241255589","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264241255589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:24:33Z","timestamp":1790695473000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264241255589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1177\/24741264241255589"],"URL":"https:\/\/doi.org\/10.1177\/24741264241255589","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]}}}